Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

American Journal of Cardiology

Volumn 104, Issue 4, 2009, Pages 459-463

  Faergeman, Ole ^a   Holme, Ingar ^b   Fayyad, Rana ^c   Bhatia, Sonal ^c   Grundy, Scott M ^d   Kastelein, John J P ^e   LaRosa, John C ^f   Larsen, Mogens Lytken ^a   Lindahl, Christina ^c   Olsson, Anders G ^g   Tikkanen, Matti J ^h   Waters, David D ⁱ   Pedersen, Terje R ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c PFIZER INC   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC VALUE; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 68049114763     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.04.008     Document Type: Article

References (20)

1. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., and Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
2. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
3. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., and Palmer G. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. Am J Cardiol 94 (2004) 720-724
4. Waters D.D., Guyton J.R., Herrington D.M., McGowan M.P., Wenger N.K., and Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 (2004) 154-158
5. Allain C.C., Poon L.S., Chan C.S., Richmond W., and Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem 20 (1974) 470-475
6. McGowan M.W., Artiss J.D., Strandbergh D.R., and Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 29 (1983) 538-542
7. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
8. Marcovina S.M., Albers J.J., Henderson L.O., and Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 39 (1993) 773-781
9. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., and Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 40 (1994) 586-592
10. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., and Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51 (2008) 724-730
11. Jeppesen J., Hein H.O., Suadicani P., and Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97 (1998) 1029-1036
12. Carlson L.A., and Bottiger L.E. Risk factors for ischaemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm Prospective Study. Acta Med Scand 218 (1985) 207-211
13. Hulley S.B., Rosenman R.H., Bawol R.D., and Brand R.J. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 302 (1980) 1383-1389
14. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
15. Brinton E.A., Eisenberg S., and Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14 (1994) 707-720
16. Parhofer K.G., and Barrett P.H. Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. J Lipid Res 47 (2006) 1620-1630
17. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., and Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298 (2007) 309-316
18. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007) 299-308
19. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., Dallongeville J., De Backer G., Ebrahim S., Gjelsvik B., Herrmann-Lingen C., Hoes A., Humphries S., Knapton M., Perk J., Priori S.G., Pyorala K., Reiner Z., Ruilope L., Sans-Menendez S., Scholte op Reimer W., Weissberg P., Wood D., Yarnell J., Zamorano J.L., Walma E., Fitzgerald T., Cooney M.T., Dudina A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Funck-Brentano C., Filippatos G., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Hellemans I., Altiner A., Bonora E., Durrington P.N., Fagard R., Giampaoli S., Hemingway H., Hakansson J., Kjeldsen S.E., Larsen M.L., Mancia G., Manolis A.J., Orth-Gomer K., Pedersen T., Rayner M., Ryden L., Sammut M., Schneiderman N., Stalenhoef A.F., Tokgozoglu L., Wiklund O., and Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28 (2007) 2375-2414
20. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421